Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
HRTX
STRONG SELLHeron Therapeutics, Inc. · Healthcare · United States · $86M · Avg Vol: $1M/d
COMPANY DESCRIPTION
Heron Therapeutics, Inc. is a commercial-stage biotechnology company focused on developing and commercializing novel therapies for unmet medical needs in oncology and pain management. The company possesses a portfolio of commercialized products and a pipeline addressing significant market opportunities in supportive care and post-operative pain. Heron is known for its innovative drug delivery technologies, including long-acting formulations, designed to improve patient convenience and outcomes.
FINANCIAL SUMMARY (USD)
| Year | 2021 | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | — | 107.7M | 127.0M | 144.3M | 154.9M | 12.9% | 150.7M | 165.7M | 175.9M | 6.6% |
| EPS | -2.24 | -1.67 | -0.80 | -0.09 | -0.12 | — | -0.18 | -0.09 | — | — |
| Shares | — | 119.2M | 150.3M | 152.1M | 188.3M | +58.0% | 189.3M | — | — | — |
| Debt | — | 157.5M | 179.6M | 177.8M | 140.6M | -3.7% | 141.6M | — | — | — |
| Equity | — | 13.6M | -34.0M | -33.7M | 14.3M | 1.8% | — | — | — | — |
| Op CF | — | -146.9M | -58.8M | -22.5M | -27.6M | — | -20.3M | — | — | — |
| Inv CF | — | -3.3M | 18.0M | 18.7M | 16.0M | — | — | — | — | — |
| Fin CF | — | 75.1M | 54.1M | 0.9M | 14.4M | — | — | — | — | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of HRTX are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| HRTX | Heron Therapeutics, Inc.(you) | $86M | 8 | STRONG SELL |
| KLRS | Kalaris Therapeutics, Inc. | $89M | 9 | STRONG SELL |
| BMEA | Biomea Fusion, Inc. | $90M | 9 | STRONG SELL |
| TELO | Telomir Pharmaceuticals, Inc. | $79M | 9 | STRONG SELL |
| CGTX | Cognition Therapeutics, Inc. | $82M | 7 | STRONG SELL |
| IBIO | iBio, Inc. | $71M | 8 | STRONG SELL |
| GANX | Gain Therapeutics, Inc. | $75M | 7 | STRONG SELL |
| ANVS | Annovis Bio, Inc. | $71M | 8 | STRONG SELL |
| ALDX | Aldeyra Therapeutics, Inc. | $92M | 4 | STRONG SELL |
| PLYX | Polaryx Therapeutics, Inc. | $102M | 6 | STRONG SELL |
Peer medians: ROE -25.5% · P/E 27.7x · Gross margin 50.5%